BioCentury | Dec 30, 2016
Clinical News

Anagrelide CR regulatory update

...Galena said FDA confirmed that a Phase III trial comparing anagrelide CR vs. best available therapy...
...“sizable subpopulation” of patients treat with anagrelide IR. Anagrelide CR is a controlled-release formulation of anagrelide...
...products. Galena Biopharma Inc. (NASDAQ:GALE), San Ramon, Calif. Product: Anagrelide CR (GALE-401) Business: Hematology Jaime De Leon anagrelide...
BioCentury | Aug 1, 2016
Clinical News

Jakafi: Phase III data

...patients receiving best available therapy. Patients received investigator’s choice of hydroxyurea, interferon, pegylated interferon, pipobroman, anagrelide...
BioCentury | Jan 18, 2016
Strategy

Shire's serial story

...Shire has no cancer therapies in its pipeline. It does market one hematology drug: Xagrid anagrelide...
BioCentury | Aug 10, 2015
Strategy

Shire's M&A stepping stone

...single cancer product on the market: Baxalta's recently acquired leukemia drug Oncaspar and Shire's Xagrid anagrelide...
...model." Of Baxalta's four late-stage cancer programs, three are for hematological malignancies. Enyedy added that Xagrid...
BioCentury | Jun 22, 2015
Clinical News

Anagrelide CR: Updated Phase II data

...Product: Anagrelide CR ( GALE-401 ) Business: Hematology Molecular target: NA Description: Controlled-release formulation of anagrelide...
BioCentury | Jun 15, 2015
Clinical News

Anagrelide CR: Additional Phase II data

...Product: Anagrelide CR ( GALE-401 ) Business: Hematology Molecular target: NA Description: Controlled-release formulation of anagrelide...
BioCentury | Jan 26, 2015
Clinical News

Anagrelide CR: Preliminary Phase II data

...Product: Anagrelide CR ( GALE-401 ) Business: Hematology Molecular target: NA Description: Controlled-release formulation of anagrelide...
BioCentury | Dec 8, 2014
Clinical News

Anagrelide CR: Completed Phase II enrollment

...Product: Anagrelide CR ( GALE-401 ) Business: Hematology Molecular target: NA Description: Controlled-release formulation of anagrelide...
BioCentury | Nov 17, 2014
Company News

AOP Orphan sales and marketing update

...AOP Orphan launched Thromboreductin anagrelide in Russia to treat essential thrombocythemia. The product comes in 0.5...
BioCentury | Sep 22, 2014
Clinical News

Anagrelide CR: Phase II started

...Product: Anagrelide CR ( GALE-401 ) Business: Hematology Molecular target: NA Description: Controlled-release formulation of anagrelide...
Items per page:
1 - 10 of 55